Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status in Female Patients With Type 2 Diabetes and Obesity
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Dual energy X-ray absorptiometry
研究概览
简要总结
GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state
详细描述
As a treatment for type 2 diabetesGlucagon like peptide -1 (Glucan-like peptide-1, GLP-1) receptor agonists plays the role of promoting insulin secretion, inhibiting glucagon secretion,and also has the central and peripheral effects,it can inhibit appetite,reduce weight.GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of overweight and type 2 diabetes mellitus
排除标准
- •Poor body condition (severe liver and kidney dysfunction)
- •Unknown causes of pancreatitis, chronic pancreatitis, pancreatic resection, stomach operation, malignant tumor, previous use of systemic corticosteroids (local or inhalation of exceptions) heart function or niacin, incomplete
- •serious endocrine disease
- •genetic disease
研究组 & 干预措施
exenatide
exenatide, 5ug, bid, 3months
干预措施: Exenatide (Drug)
结局指标
主要结局
Dual energy X-ray absorptiometry
时间窗: 3 month
fat distribution
次要结局
- lab testing(3 month)
研究者
Zhang Manna
Professor
Shanghai 10th People's Hospital
